```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05   CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14   2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14   2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14   CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21   IPC search and display fields enhanced in CA/CAplus with the
                   IPC reform
 NEWS  8  DEC 23   New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                   USPAT2
 NEWS  9  JAN 13   IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13   New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                   INPADOC
 NEWS 11  JAN 17   Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17   IPC 8 in the WPI family of databases including WPIFV
 NEWS 13  JAN 30   Saved answer limit increased
 NEWS 14  JAN 31   Monthly current-awareness alert (SDI) frequency
                   added to TULSA

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:13:24 ON 07 FEB 2006

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
```

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:13:33 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5
DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10521930b.str



chain nodes :
9 12 17 24 28 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
ring nodes :
1 2 3 4 5 6 7 8 10 11 13 14 15 16 18 19 20 21 22 23 25 26 27 29 30 31 32 33 34 35 36 37 38 39
chain bonds :
3-52 8-9 10-53 11-12 13-54 15-55 16-17 18-56 21-40 23-24 25-47 27-28 40-41 40-57 41-42 41-45 42-43 42-46 43-44 43-58 47-48 47-49 49-50 49-51

ring bonds :
1-2 1-6 1-38 2-3 3-4 4-5 5-6 5-7 7-8 8-10 10-11 11-13 13-14 14-15
15-16 16-18 18-19 19-20 20-21 21-22 22-23 23-25 25-26 26-27 27-29 29-30
30-31 31-32 32-33 33-34 34-35 35-36 36-37 37-39 38-39
exact/norm bonds :
1-2 1-6 1-38 2-3 3-4 4-5 5-6 5-7 7-8 8-9 8-10 10-11 11-12 11-13 13-14
14-15 15-16 16-17 16-18 18-19 19-20 20-21 21-22 22-23 23-24 23-25 25-26
26-27 27-28 27-29 29-30 30-31 31-32 32-33 33-34 34-35 35-36 36-37 37-39
38-39 41-45 42-46 43-44 47-48 49-50 49-51
exact bonds :
3-52 10-53 13-54 15-55 18-56 21-40 25-47 40-41 40-57 41-42 42-43 43-58
47-49

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 28:CLASS
29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS
46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS
54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:14:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:14:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L3 4 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'CAPLUS' ENTERED AT 13:14:19 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 3 L3

=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:80497 CAPLUS
DOCUMENT NUMBER: 140:139542
TITLE: Chondropsin-class antitumor vacuolar ATPase inhibitor compounds, compositions, and methods of use
INVENTOR(S): Boyd, Michael R.; Gustafson, Kirk R.
PATENT ASSIGNEE(S): The Government of the United States of America, Represented by the Secretary Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004009079	A1	20040129	WO 2003-US23290	20030724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493821	AA	20040129	CA 2003-2493821	20030724
EP 1542674	A1	20050622	EP 2003-751813	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005176810	A1	20050811	US 2003-521930	20030724
PRIORITY APPLN. INFO.:			US 2002-398092P	P 20020724
			WO 2003-US23290	W 20030724

OTHER SOURCE(S): MARPAT 140:139542

AB The invention discloses the title compds., compns. comprising a therapeutically effective amount of at least one of them, alone or in combination with at least one addnl. therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase. Isolation and purification of poecillastrin A is described.

IT **471913-55-0P**, Poecillastrin A
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(chondropsin-class antitumor vacuolar ATPase inhibitor compds., compns., and methods of use)

RN 471913-55-0 CAPLUS

CN 14,34-Dioxa-17-azabicyclo[28.3.1]tetratriaconta-6,10,19,21,25,27-hexaene-16-acetic acid, 13-[2,4-dihydroxy-1-methyl-3-[[(8E)-3,7,11-trihydroxy-12-[[(2E)-7-hydroxy-4,4,6,8-tetramethyl-1,5-dioxo-2-nonenyl]amino]-2,6,8,10,10,14-hexamethyl-1-oxo-8-pentadecenyl]amino]pentyl]-α,3,5,9-tetrahydroxy-29-methoxy-4,6,8,10,32-pentamethyl-15,18-dioxo-, (6E,10E,19E,21E,25E,27E)-(-)- (9CI) (CA INDEX NAME)

Rotation (-).
Double bond geometry as described by E or Z.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **651726-41-9 651726-42-0 651726-43-1**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chondropsin-class antitumor vacuolar ATPase inhibitor compds., compns., and methods of use)

RN 651726-41-9 CAPLUS

CN 14,34-Dioxa-17-azabicyclo[28.3.1]tetratriaconta-6,10,19,21,25,27-hexaene-16-acetic acid, 13-(3-amino-2,4-dihydroxy-1-methylpentyl)-α,3,5,9-tetrahydroxy-29-methoxy-4,6,8,10,32-pentamethyl-15,18-dioxo- (9CI) (CA INDEX NAME)

Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



RN 651726-42-0 CAPLUS
CN 14,34-Dioxa-17-azabicyclo[28.3.1]tetratriaconta-6,10,19,21,25,27-hexaene-16-acetic acid, 13-[2,4-dihydroxy-1-methyl-3-[[3,7,11-trihydroxy-12-[[7-hydroxy-4,4,6,8-tetramethyl-1,5-dioxo-2-nonenyl]amino]-2,6,8,10,10,14-hexamethyl-1-oxo-8-pentadecenyl]amino]pentyl]-α,3,5,9-tetrahydroxy-29-methoxy-4,6,8,10,32-pentamethyl-15,18-dioxo- (9CI) (CA INDEX NAME)

Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 651726-43-1 CAPLUS
CN 14,34-Dioxa-17-azabicyclo[28.3.1]tetratriaconta-6,10,19,21,25,27-hexaene-16-acetic acid, 13-[2,4-dihydroxy-1-methyl-3-[[3,7,11-trihydroxy-12-[[7-hydroxy-4,4,6,8-tetramethyl-1,5-dioxo-2-nonenyl]amino]-2,6,8,10,10,14-hexamethyl-1-oxo-8-pentadecenyl]amino]pentyl]-α,3,5,9-tetrahydroxy-29-methoxy-4,6,8,10,32-pentamethyl-15,18-dioxo-, (1S,30S,32S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.
Currently available stereo shown.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:871548 CAPLUS
DOCUMENT NUMBER: 140:87244
TITLE: Identification of a New Chondropsin Class of Antitumor Compound That Selectively Inhibits V-ATPases
AUTHOR(S): Bowman, Emma Jean; Gustafson, Kirk R.; Bowman, Barry J.; Boyd, Michael R.
CORPORATE SOURCE: Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, CA, 95064, USA
SOURCE: Journal of Biological Chemistry (2003), 278(45), 44147-44152
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors identify a new naturally occurring class of inhibitor of vacuolar H+-ATPases (V-ATPases) isolated from vacuolar membranes of Neurospora crassa and from chromaffin granule membranes of Bos taurus. To date, the new class includes six chondropsins and poecillastrin A, large polyketide-derived macrolide lactams with 33-37 membered rings. In the National Cancer Institute's 60-cell screen the chondropsin class showed a tumor cell growth inhibitory fingerprint essentially indistinguishable from that of the bafilomycin/concanamycin and the salicylihalamide/lobatamide classes of well-established V-ATPase inhibitors. Half-maximal inhibition of V-ATPase activity in vitro occurred at 0.04-0.7 μM for the fungal vacuolar V-ATPase and at 0.4 to >10 μM for the chromaffin granule V-ATPase. Thus, the new inhibitors are somewhat less potent than the other two classes, which typically have Ki values of <10 nM for V-ATPases, and the new inhibitors differ from the other two classes in their specificity. The bafilomycin class inhibits all eucaryotic V-ATPases, the salicylihalamide class inhibits mammalian V-ATPases but not fungal V-ATPases, and the new chondropsin class inhibits the N. crassa V-ATPase better than the chromaffin granule V-ATPase. Two mutations in the N. crassa V-ATPase that affect the binding of bafilomycin had small but reproducible effects on the affinity of chondropsins for the V-ATPase, suggesting the possibility of a similar mechanism of inhibition.

IT **471913-55-0**, Poecillastrin A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(identification of a new chondropsin class of antitumor compound that selectively inhibits V-ATPases)

RN 471913-55-0 CAPLUS

CN 14,34-Dioxa-17-azabicyclo[28.3.1]tetratriaconta-6,10,19,21,25,27-hexaene-16-acetic acid, 13-[2,4-dihydroxy-1-methyl-3-[[(8E)-3,7,11-trihydroxy-12-[[(2E)-7-hydroxy-4,4,6,8-tetramethyl-1,5-dioxo-2-nonenyl]amino]-2,6,8,10,10,14-hexamethyl-1-oxo-8-pentadecenyl]amino]pentyl]-α,3,5,9-tetrahydroxy-29-methoxy-4,6,8,10,32-pentamethyl-15,18-dioxo-, (6E,10E,19E,21E,25E,27E)-(-)- (9CI) (CA INDEX NAME)

Rotation (-).

Double bond geometry as described by E or Z.

Currently available stereo shown.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:635740 CAPLUS

DOCUMENT NUMBER: 137:310745

TITLE: Application of High-Field NMR and Cryogenic Probe Technologies in the Structural Elucidation of Poecillastrin A, a New Antitumor Macrolide Lactam from the Sponge Poecillastra Species

AUTHOR(S): Rashid, Mohammad A.; Gustafson, Kirk R.; Crouch, Ronald C.; Groweiss, Amiram; Pannell, Lewis K.; Van, Que N.; Boyd, Michael R.

CORPORATE SOURCE: Molecular Targets Drug Discovery Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, 21702-1201, USA

SOURCE: Organic Letters (2002), 4(19), 3293-3296
CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Poecillastrin A (I), a new polyketide-derived macrolide lactam, was isolated from a deep-water collection of the marine sponge Poecillastra species. The structure of I was assigned using NMR data acquired at 500 MHz with an inverse-detection cryogenic probe and at 800 MHz with a room-temperature probe.

IT **471913-55-0P**, Poecillastrin A
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process)
(high-field NMR and cryogenic probe technologies in the structural elucidation of poecillastrin A from Poecillastra species)

RN 471913-55-0 CAPLUS

CN 14,34-Dioxa-17-azabicyclo[28.3.1]tetratriaconta-6,10,19,21,25,27-hexaene-16-acetic acid, 13-[2,4-dihydroxy-1-methyl-3-[[(8E)-3,7,11-trihydroxy-12-[[(2E)-7-hydroxy-4,4,6,8-tetramethyl-1,5-dioxo-2-nonenyl]amino]-2,6,8,10,10,14-hexamethyl-1-oxo-8-pentadecenyl]amino]pentyl]-α,3,5,9-tetrahydroxy-29-methoxy-4,6,8,10,32-pentamethyl-15,18-dioxo-, (6E,10E,19E,21E,25E,27E)-(-)- (9CI) (CA INDEX NAME)

Rotation (-).
Double bond geometry as described by E or Z.
Currently available stereo shown.







REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.71	183.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

FILE 'MARPAT' ENTERED AT 13:16:06 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1969-PRESENT (VOL 144 ISS 6 (20060205/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1969-1987

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6965040 15 NOV 2005
DE 1020040544 17 NOV 2005
EP 1600439 30 NOV 2005
JP 2005336157 08 DEC 2005
WO 2005121067 22 DEC 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 13:16:35 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 189 TO ITERATE

100.0% PROCESSED 189 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L5 1 SEA SSS FUL L1

=> d ibib abs fqhit

L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 140:139542 MARPAT
TITLE: Chondropsin-class antitumor vacuolar ATPase inhibitor compounds, compositions, and methods of use
INVENTOR(S): Boyd, Michael R.; Gustafson, Kirk R.
PATENT ASSIGNEE(S): The Government of the United States of America, Represented by the Secretary Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009079	A1	20040129	WO 2003-US23290	20030724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493821	AA	20040129	CA 2003-2493821	20030724
EP 1542674	A1	20050622	EP 2003-751813	20030724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005176810	A1	20050811	US 2003-521930	20030724
PRIORITY APPLN. INFO.:			US 2002-398092P	20020724
			WO 2003-US23290	20030724

AB The invention discloses the title compds., compns. comprising a therapeutically effective amount of at least one of them, alone or in combination with at least one addnl. therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase. Isolation and purification of poecillastrin A is described.

MSTR 1







G1 = OH
G6 = OH
Patent location: claim 1
Note: or pharmaceutically acceptable salts or prodrugs

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	122.61	306.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.71	-2.96

STN INTERNATIONAL LOGOFF AT 13:17:18 ON 07 FEB 2006